Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Mutation S115T in IMP-Type Metallo-β-Lactamases Compensates for Decreased Expression Levels Caused by Mutation S119G.

Zhang CJ, Faheem M, Dang P, Morris MN, Kumar P, Oelschlaeger P.

Biomolecules. 2019 Nov 11;9(11). pii: E724. doi: 10.3390/biom9110724.

2.

Real-Time Monitoring of NDM-1 Activity in Live Bacterial Cells by Isothermal Titration Calorimetry: A New Approach To Measure Inhibition of Antibiotic-Resistant Bacteria.

Zhang YJ, Wang WM, Oelschlaeger P, Chen C, Lei JE, Lv M, Yang KW.

ACS Infect Dis. 2018 Dec 14;4(12):1671-1678. doi: 10.1021/acsinfecdis.8b00147. Epub 2018 Nov 5.

PMID:
30383355
3.

Virtual Screening and Experimental Testing of B1 Metallo-β-lactamase Inhibitors.

Kang JS, Zhang AL, Faheem M, Zhang CJ, Ai N, Buynak JD, Welsh WJ, Oelschlaeger P.

J Chem Inf Model. 2018 Sep 24;58(9):1902-1914. doi: 10.1021/acs.jcim.8b00133. Epub 2018 Aug 29.

4.

Rhodanine as a Potent Scaffold for the Development of Broad-Spectrum Metallo-β-lactamase Inhibitors.

Xiang Y, Chen C, Wang WM, Xu LW, Yang KW, Oelschlaeger P, He Y.

ACS Med Chem Lett. 2018 Mar 22;9(4):359-364. doi: 10.1021/acsmedchemlett.7b00548. eCollection 2018 Apr 12.

5.

Change in self-assessed comfort level of first-year pharmacy students as an alternative approach to measure teaching effectiveness and learning outcomes.

Oelschlaeger P.

Curr Pharm Teach Learn. 2017 May;9(3):383-390. doi: 10.1016/j.cptl.2017.01.005. Epub 2017 Apr 1.

PMID:
29233275
6.

Azolylthioacetamides as a potent scaffold for the development of metallo-β-lactamase inhibitors.

Xiang Y, Chang YN, Ge Y, Kang JS, Zhang YL, Liu XL, Oelschlaeger P, Yang KW.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5225-5229. doi: 10.1016/j.bmcl.2017.10.038. Epub 2017 Oct 20.

PMID:
29122480
7.

Carbamylmethyl Mercaptoacetate Thioether: A Novel Scaffold for the Development of L1 Metallo-β-lactamase Inhibitors.

Chang YN, Xiang Y, Zhang YJ, Wang WM, Chen C, Oelschlaeger P, Yang KW.

ACS Med Chem Lett. 2017 Apr 24;8(5):527-532. doi: 10.1021/acsmedchemlett.7b00058. eCollection 2017 May 11.

8.

Functionalizing the γ-Position of α-Diazo-β-ketoesters.

Nguyen TQ, Alqurafi M, Edwards C, Nguyen P, Kim J, Casco S, Bennet M, Chiang C, Lohry M, Cox M, Meshram B, Le D, Kim E, Smriti S, Oelschlaeger P, Buynak JD.

Tetrahedron Lett. 2016 Jun 27;57(30):3330-3333. Epub 2016 Jun 16.

9.

Optimization of amino acid thioesters as inhibitors of metallo-β-lactamase L1.

Liu XL, Yang KW, Zhang YJ, Ge Y, Xiang Y, Chang YN, Oelschlaeger P.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4698-4701. doi: 10.1016/j.bmcl.2016.08.048. Epub 2016 Aug 22.

PMID:
27595424
10.

Triazolylthioacetamide: A Valid Scaffold for the Development of New Delhi Metallo-β-Lactmase-1 (NDM-1) Inhibitors.

Zhai L, Zhang YL, Kang JS, Oelschlaeger P, Xiao L, Nie SS, Yang KW.

ACS Med Chem Lett. 2016 Feb 16;7(4):413-7. doi: 10.1021/acsmedchemlett.5b00495. eCollection 2016 Apr 14.

11.

Elucidating the Role of Residue 67 in IMP-Type Metallo-β-Lactamase Evolution.

LaCuran AE, Pegg KM, Liu EM, Bethel CR, Ai N, Welsh WJ, Bonomo RA, Oelschlaeger P.

Antimicrob Agents Chemother. 2015 Dec;59(12):7299-307. doi: 10.1128/AAC.01651-15. Epub 2015 Sep 14.

12.

Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.

Alsamarah A, LaCuran AE, Oelschlaeger P, Hao J, Luo Y.

PLoS One. 2015 Jul 2;10(7):e0132221. doi: 10.1371/journal.pone.0132221. eCollection 2015.

13.

Amino Acid Thioester Derivatives: A Highly Promising Scaffold for the Development of Metallo-β-lactamase L1 Inhibitors.

Liu XL, Shi Y, Kang JS, Oelschlaeger P, Yang KW.

ACS Med Chem Lett. 2015 Apr 23;6(6):660-4. doi: 10.1021/acsmedchemlett.5b00098. eCollection 2015 Jun 11.

14.

Triethysilyl Enol Ethers in the Synthesis of Carbapenem Precursors.

Nguyen TQ, Chai W, Gu J, Cook K, Kim E, Goetz S, Farni Z, Chepuru M, Cox M, Nguyen P, Raja H, Magistrado P, Michael F, Oelschlaeger P, Buynak JD.

Tetrahedron Lett. 2015 Jun 3;56(23):3385-3389.

15.

Meropenem and chromacef intermediates observed in IMP-25 metallo-β-lactamase-catalyzed hydrolysis.

Oelschlaeger P, Aitha M, Yang H, Kang JS, Zhang AL, Liu EM, Buynak JD, Crowder MW.

Antimicrob Agents Chemother. 2015 Jul;59(7):4326-30. doi: 10.1128/AAC.04409-14. Epub 2015 Apr 27.

16.

Azolylthioacetamide: A Highly Promising Scaffold for the Development of Metallo-β-lactamase Inhibitors.

Yang SK, Kang JS, Oelschlaeger P, Yang KW.

ACS Med Chem Lett. 2015 Feb 12;6(4):455-60. doi: 10.1021/ml500534c. eCollection 2015 Apr 9.

17.

Understanding the determinants of substrate specificity in IMP family metallo-β-lactamases: the importance of residue 262.

Pegg KM, Liu EM, George AC, LaCuran AE, Bethel CR, Bonomo RA, Oelschlaeger P.

Protein Sci. 2014 Oct;23(10):1451-60. doi: 10.1002/pro.2530. Epub 2014 Aug 20.

18.

Diaryl-substituted azolylthioacetamides: Inhibitor discovery of New Delhi metallo-β-lactamase-1 (NDM-1).

Zhang YL, Yang KW, Zhou YJ, LaCuran AE, Oelschlaeger P, Crowder MW.

ChemMedChem. 2014 Nov;9(11):2445-8. doi: 10.1002/cmdc.201402249. Epub 2014 Jul 22.

PMID:
25048031
19.

New β-phospholactam as a carbapenem transition state analog: Synthesis of a broad-spectrum inhibitor of metallo-β-lactamases.

Yang KW, Feng L, Yang SK, Aitha M, LaCuran AE, Oelschlaeger P, Crowder MW.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5855-9. doi: 10.1016/j.bmcl.2013.08.098. Epub 2013 Sep 8.

20.

Exploring the conformational and reactive dynamics of biomolecules in solution using an extended version of the glycine reactive force field.

Monti S, Corozzi A, Fristrup P, Joshi KL, Shin YK, Oelschlaeger P, van Duin AC, Barone V.

Phys Chem Chem Phys. 2013 Sep 28;15(36):15062-77. doi: 10.1039/c3cp51931g.

PMID:
23925839
21.

Biochemical characterization of IMP-30, a metallo-β-lactamase with enhanced activity toward ceftazidime.

Pegg KM, Liu EM, Lacuran AE, Oelschlaeger P.

Antimicrob Agents Chemother. 2013 Oct;57(10):5122-6. doi: 10.1128/AAC.02341-12. Epub 2013 Jul 8.

22.

The sequence-activity relationship between metallo-β-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure.

Liu EM, Pegg KM, Oelschlaeger P.

Antimicrob Agents Chemother. 2012 Dec;56(12):6403-6. doi: 10.1128/AAC.01440-12. Epub 2012 Sep 24.

23.

Systematic analysis of metallo-β-lactamases using an automated database.

Widmann M, Pleiss J, Oelschlaeger P.

Antimicrob Agents Chemother. 2012 Jul;56(7):3481-91. doi: 10.1128/AAC.00255-12. Epub 2012 Apr 30.

24.

Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a gram-negative bacterium.

Xiong X, Bromley EH, Oelschlaeger P, Woolfson DN, Spencer J.

Nucleic Acids Res. 2011 May;39(9):3917-27. doi: 10.1093/nar/gkq1296. Epub 2011 Jan 11.

25.

Intramolecular interactions between the protease and structural domains are important for the functions of serine protease autotransporters.

Tsang C, Malik H, Nassman D, Huang A, Tariq F, Oelschlaeger P, Stathopoulos C.

Infect Immun. 2010 Aug;78(8):3335-45. doi: 10.1128/IAI.00129-10. Epub 2010 May 17.

26.

Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?

Oelschlaeger P, Ai N, Duprez KT, Welsh WJ, Toney JH.

J Med Chem. 2010 Apr 22;53(8):3013-27. doi: 10.1021/jm9012938. No abstract available.

27.

A binding free energy decomposition approach for accurate calculations of the fidelity of DNA polymerases.

Rucker R, Oelschlaeger P, Warshel A.

Proteins. 2010 Feb 15;78(3):671-80. doi: 10.1002/prot.22596.

28.

Outsmarting metallo-beta-lactamases by mimicking their natural evolution.

Oelschlaeger P.

J Inorg Biochem. 2008 Dec;102(12):2043-51. doi: 10.1016/j.jinorgbio.2008.05.007. Epub 2008 May 28. Review.

PMID:
18602162
30.

Hydroxyl groups in the betabeta sandwich of metallo-beta-lactamases favor enzyme activity: Tyr218 and Ser262 pull down the lid.

Oelschlaeger P, Pleiss J.

J Mol Biol. 2007 Feb 9;366(1):316-29. Epub 2006 Nov 11.

PMID:
17157873
32.
33.

Computationally designed variants of Escherichia coli chorismate mutase show altered catalytic activity.

Lassila JK, Keeffe JR, Oelschlaeger P, Mayo SL.

Protein Eng Des Sel. 2005 Apr;18(4):161-3. Epub 2005 Apr 8.

PMID:
15820980
35.
36.

Insight into the mechanism of the IMP-1 metallo-beta-lactamase by molecular dynamics simulations.

Oelschlaeger P, Schmid RD, Pleiss J.

Protein Eng. 2003 May;16(5):341-50.

PMID:
12826725
37.

Identification of factors impeding the production of a single-chain antibody fragment in Escherichia coliby comparing in vivo and in vitro expression.

Oelschlaeger P, Lange S, Schmitt J, Siemann M, Reuss M, Schmid RD.

Appl Microbiol Biotechnol. 2003 Apr;61(2):123-32. Epub 2003 Jan 28.

PMID:
12655454

Supplemental Content

Loading ...
Support Center